Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors
申请人:Hu H. Essa
公开号:US20070287716A1
公开(公告)日:2007-12-13
The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
PYRIMIDINE AND QUINOLINE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS
申请人:Merck & Co., Inc.
公开号:EP1809608A1
公开(公告)日:2007-07-25
[EN] PYRIMIDINE AND QUINOLINE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] POTENTIALISATEURS DE PYRIMIDINE ET QUINOLINE DES RECEPTEURS METABOTROPIQUES DU GLUTAMATE
申请人:MERCK & CO INC
公开号:WO2006049968A1
公开(公告)日:2006-05-11
[EN] The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. [FR] L'invention concerne des composés qui sont des potentialisateurs des récepteurs métabotropiques du glutamate, notamment le récepteur mGluR2, et utiles dans le traitement ou la prévention de troubles neurologiques et psychiatriques associés à un dysfonctionnement du glutamate et des maladies dans lesquelles les récepteurs métabotropiques du glutamate sont impliqués. L'invention concerne également des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés et compositions dans la prévention ou le traitement de telles maladies dans lesquelles les récepteurs métabotropiques sont impliqués.